Welcome to our dedicated page for CNS Pharmaceuticals news (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on CNS Pharmaceuticals stock.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) is a clinical-stage biopharmaceutical company pioneering treatments for aggressive central nervous system cancers. This page provides investors and medical stakeholders with timely updates on the company’s groundbreaking therapies, including Berubicin for glioblastoma and TPI 287 for advanced CNS tumors.
Access consolidated updates on clinical trial progress, FDA designations, and strategic partnerships. Our news feed covers critical developments in the company’s pipeline, including Phase II results for Berubicin – the first anthracycline to cross the blood-brain barrier – and preclinical advancements for TPI 287’s microtubule-stabilizing mechanism.
Key coverage areas include regulatory milestones, peer-reviewed research publications, and collaborations with leading institutions like MD Anderson Cancer Center. Bookmark this page for verified updates on CNS Pharmaceuticals’ efforts to address unmet needs in neuro-oncology through innovative science and targeted drug development.
CNS Pharmaceuticals (NASDAQ:CNSP) has announced a registered direct offering of 17,647,060 shares of common stock priced at-the-market at $0.17 per share. The offering, expected to close around October 24, 2024, aims to raise approximately $3 million in gross proceeds. The company plans to use the net proceeds for working capital and general corporate purposes. A.G.P./Alliance Global Partners is serving as the sole placement agent for this offering, which is being conducted under an effective shelf registration statement.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, announced its participation in a Virtual Investor KOL Connect segment. The event featured key members of the CNS management team, including:
- John Climaco, Chief Executive Officer
- Dr. Sandra Silberman, Chief Medical Officer
- Dr. Don Picker, Chief Scientific Officer
Additionally, Dr. Samuel Goldlust, a leading Neuro-Oncologist and Key Opinion Leader, joined the segment. Dr. Goldlust currently serves as the Medical Director of Neuro-Oncology at Saint Luke's Health System and was previously an investigator in CNS's global potentially pivotal study of Berubicin.
The segment covered a corporate overview, discussed the unmet need in glioblastoma multiforme (GBM), and explored the opportunities for CNS Pharmaceuticals in this field.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the 2024 Healthcare Virtual Summit presented by Maxim Group John Climaco, CEO of CNS Pharmaceuticals, will engage in a fireside chat on Wednesday, October 16th at 4:00 PM ET.
The summit will feature a series of presentations and interactive discussions with CEOs and key management from various healthcare sectors, including biotechnology, diagnostics, medical devices, and healthcare information technology. Maxim Senior Analysts will host these sessions and conduct several topical industry panels.
Interested participants can attend the virtual event by signing up for an M-Vest membership. Further updates about the summit will be provided to registered attendees.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the 24th Annual Biotech in Europe Forum. John Climaco, the company's CEO, is scheduled to present on Wednesday, September 25, 2024, at 1:55 PM CEST in Basel, Switzerland.
The presentation will be available as a video webcast on demand for registered attendees through the conference presenters portal. Additionally, the company's management team will be available for in-person one-on-one meetings with qualified investors attending the conference.
This event provides CNS Pharmaceuticals with an opportunity to showcase its developments in primary and metastatic cancer treatments, potentially attracting investor interest and fostering industry connections.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has regained compliance with Nasdaq's equity requirement. The company received notice from Nasdaq on September 10, 2024, confirming its compliance with Listing Rule 5550(b)(1). This development is subject to a one-year Nasdaq Mandatory Panel Monitor related to the equity requirement. With this compliance issue resolved, Nasdaq has informed CNS Pharmaceuticals that the matter is now closed.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York, NY.
Key points:
- CEO John Climaco will present at the conference
- Management will be available for one-on-one meetings with qualified investors
- A video webcast of the presentation will be available on-demand from September 9, 2024, at 7:00 AM ET
- The webcast will be accessible on the Company's website and archived for 90 days
This presentation offers an opportunity for CNS Pharmaceuticals to showcase its developments and engage with the investment community.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar. The event is scheduled for Wednesday, August 28, 2024, at 3:20 PM ET.
John Climaco, the company's Chief Executive Officer, will present and discuss recent corporate developments during the webinar. This presentation offers an opportunity for investors and interested parties to gain insights into CNS Pharmaceuticals' latest advancements and future plans in the field of cancer treatment.
Participants can register for the event through the provided registration link, allowing them to join the live webcast and learn more about CNS Pharmaceuticals' innovative approaches to addressing primary and metastatic cancers in the brain and central nervous system.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in a Virtual Investor CEO Connect segment. The event, scheduled for Monday, August 26, 2024, at 12:00 PM ET, will feature CEO John Climaco.
The segment will include a brief presentation by Mr. Climaco, followed by an interactive Q&A session. Investors can submit questions live during the event or in advance via email to cnsp@jtcir.com. The live video webcast will be available on the company's website, with a replay accessible for 90 days following the presentation.
CNS Pharmaceuticals (NASDAQ:CNSP) reported its Q2 2024 financial results and provided updates on its clinical programs. Key highlights include:
1. Completion of enrollment in the potentially pivotal GBM study for Berubicin, with topline data expected in H1 2025.
2. Strategic in-licensing of TPI 287, synergistic with Berubicin, for recurrent GBM treatment.
3. Net loss of $2.5 million for Q2 2024, down from $4.0 million in Q2 2023.
4. R&D expenses decreased to $1.1 million from $2.8 million year-over-year.
5. Cash position of $1.5 million as of June 30, 2024, with additional $12.4 million raised by August 14, 2024.
The company is focused on developing novel treatments for brain and central nervous system cancers, particularly glioblastoma multiforme (GBM).
CNS Pharmaceuticals (NASDAQ:CNSP) has expanded its pipeline by in-licensing TPI 287, a late-stage, potential blood-brain barrier permeable abeotaxane for treating brain malignancies. The company obtained exclusive rights from Cortice Biosciences in exchange for 616,698 shares and potential future milestone payments. TPI 287 has shown promising results in over 350 patients, including a 60% objective response rate and 96% disease control rate in a Phase 1 study for recurrent glioblastoma (GBM). CNS plans to engage with the FDA to design a registration study for TPI 287 in recurrent GBM, aiming to start in 2025. This complements their ongoing Berubicin program, with topline results expected in H1 2025. The company also launched a new corporate brand and website to align with its focus on GBM treatment.
FAQ
What is the current stock price of CNS Pharmaceuticals (CNSP)?
What is the market cap of CNS Pharmaceuticals (CNSP)?
